Niagen Bioscience (NAGE) Q2 FY26 earnings call

Niagen Bioscience is transforming from a NAD supplement company into a broader science-driven platform, expanding into consumer health, skincare, IV injections, and pharmaceuticals. The core business provides a solid financial foundation, enabling strategic investments in new verticals for long-term growth, with a focus on disciplined capital allocation and maintaining cash flow positivity.